Check out this CSL share price forecast for 2026. It’s hard to believe!
Image source: Getty Images
Global blood products company CSL Ltd (ASX: CSL) has had a year to forget from a share price point of view and is changing hands not far off its lows over the past 12 months.
But the analysts at RBC Capital Markets believe the stock is oversold, and “while CSL is facing increased competition in its core markets and a backdrop of weak flu vaccinations, we believe the large share price fall now presents a compelling investment opportunity”.
CSL Chair Brian McNamee addressed the underperformance at the company’s annual general meeting held in late October, and agreed that the fall in the company’s share price, from highs of $282.20 to as low as $168, had been “disappointing”.
But he said the company was…
